Clinical Trial Update: Twice Daily Titration Study of Bifeprunox in Subjects With Schizophrenia [Phase 2]

View source ↗

Summary

Phase 2 study evaluating twice-daily titration of bifeprunox in schizophrenia and schizoaffective disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizoaffective Disorder
• Schizophrenia

Drugs mentioned

• Bifeprunox (bifeprunox)

Snippet

Sponsor: Solvay Pharmaceuticals | Conditions: Schizophrenia, Schizoaffective Disorder | Phase 2 | Status: COMPLETED